Follow-The-Filings

MDGL

Madrigal Pharmaceuticals Inc. COM Equity as of 2026 Q1

  • 4 Owners
  • Max 23.4%
  • $734M
  • 1 new 1 add 1 reduce

Who owns this now

Largest portfolio weights among featured holders · max 23.4% (John Paulson - Paulson & Co.) · not free-float ownership

  1. John Paulson reduce 23.4%
  2. Palo Alto Investors new 0.1%
  3. Ron Baron add 0.01%
  4. Farallon Capital Management 0.01%

Holders

sorted by % of portfolio · long equity only

history
John Paulson - Paulson & Co. 2026 Q1 23.4% Reduce −18.5% 1,392,188 $729M hist
Palo Alto Investors 2026 Q1 0.1% New 0.1% 1,787 $935K hist
Ron Baron - Bamco Inc. /NY/ (Baron Capital) 2026 Q1 0.01% Add +112.0% 5,300 $3M hist
Farallon Capital Management 2026 Q1 0.01% Hold 3,319 $2M hist

4 current · options excluded

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue — $180.13M $958.4M
Gross profit * — $173.9M —
Gross margin * — 96.5% —
Net income -$76.9M -$465.89M -$288.28M
Net margin * — -258.6% -30.1%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $637.28M $1.03B $1.25B
Total non-current assets * $3.27M $9.32M $13.82M
Total assets $640.55M $1.04B $1.26B
Total current liabilities $118.55M $169.28M $310.29M
Total non-current liabilities $116.67M $118.59M $346.61M
Total equity $405.33M $754.38M $602.69M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$324.23M -$455.57M -$189.55M
Cash from investing -$502.52M -$274.39M $32.32M
Cash from financing $595.12M $735.06M $255.98M
Net change in cash -$231.63M $5.1M $98.76M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

Ownership over time

filing count by report period · click a bar for that quarter’s holders